AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8839509 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene without omeprazole (low gastric pH)
Number of subjects: 12
Study 1501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-fixated IOLs
Number of subjects: 600
Study 1501083 — intervention group
Group type: COMPARATOR
Intervention: Sulcus-fixated IOLs
Number of subjects: 600
Study 1501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece IOLs (sulcus-fixated)
Number of subjects: 600
Study 1501083 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece IOLs
Number of subjects: 600
Study 1501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Biconvex design
Number of subjects: 600
Study 1501083 — intervention group
Group type: COMPARATOR
Intervention: Plano-convex or laser ridge configurations
Number of subjects: 600
Study 6339349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml HBIG at birth, 3 months, and 6 months
Number of subjects: 185
Study 6339349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml HBIG at birth only
Number of subjects: 185
Study 6339349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 31504693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime protein (30 g casein) 30 min post-resistance exercise
Number of subjects: 13
Study 31504693 — intervention group
Group type: COMPARATOR
Intervention: Presleep placebo (0 g casein) 30 min before bed
Number of subjects: 13
Study 30653534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin fortified beverage (FB, 1.5ml/kg)
Number of subjects: 20
Study 30653534 — intervention group
Group type: COMPARATOR
Intervention: Coloured water (placebo, PL)
Number of subjects: 20
Study 28587789 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly albiglutide
Number of subjects: 0
Study 28587789 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 26060584 — intervention group
Group type: EXPERIMENTAL
Intervention: Active UH-LF-rTMS
Number of subjects: 18
Study 26060584 — intervention group
Group type: COMPARATOR
Intervention: Sham UH-LF-rTMS
Number of subjects: 18
Study 23624142 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical sequences (ABCDCBA)
Number of subjects: 0
Study 23624142 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical sequences (ABCDBCA)
Number of subjects: 0
Study 23624142 — intervention group
Group type: EXPERIMENTAL
Intervention: Static body postures
Number of subjects: 0
Study 23624142 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sequences
Number of subjects: 0
Study 21552073 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraSuit
Number of subjects: 20
Study 21552073 — intervention group
Group type: COMPARATOR
Intervention: control suit
Number of subjects: 20
Study 19916639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (promoting physical activity and internal motivation for exercise and weight loss)
Number of subjects: 239
Study 19916639 — intervention group
Group type: COMPARATOR
Intervention: Control group (general health education)
Number of subjects: 239
Study 17716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 293
Study 17716324 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 293
Study 14981370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with desogestrel (DG/EE)
Number of subjects: 35
Study 14981370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with levonorgestrel (LNG/EE)
Number of subjects: 35
Study 14981370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with both preparations (LNG/EE and DG/EE)
Number of subjects: 35
Study 11712093 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (n=528) or artemether (n=11)
Number of subjects: 461
Study 11712093 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with artemisinin
Number of subjects: 461
Study 11712093 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin treatment
Number of subjects: 461
Study 11712093 — intervention group
Group type: COMPARATOR
Intervention: Birth outcomes
Number of subjects: 461
Study 9151026 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treated circuits (Duraflo II)
Number of subjects: 805
Study 9151026 — intervention group
Group type: COMPARATOR
Intervention: Untreated circuit
Number of subjects: 805
Study 7951083 — intervention group
Group type: EXPERIMENTAL
Intervention: Berodual (1 dose = 0.02 mg ipratropium bromide + 0.05 mg fenoterol), administered 3 x 1 dose/daily for 14 days
Number of subjects: 14
Study 7951083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent, 1 dose = 0.02 mg), administered 3 x 2 doses/daily for 14 days
Number of subjects: 14
Study 7951083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec, 1 dose = 0.2 mg), administered 3 x 2 doses/daily for 14 days
Number of subjects: 14
Study 3616916 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented small group sessions (POSGS) on thyroid disease
Number of subjects: 42
Study 3616916 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented small group sessions (POSGS) on breast disease
Number of subjects: 42
Study 3616916 — intervention group
Group type: COMPARATOR
Intervention: Didactic lectures (DL) on thyroid disease
Number of subjects: 42
Study 3616916 — intervention group
Group type: COMPARATOR
Intervention: Didactic lectures (DL) on breast disease
Number of subjects: 42
Study 29303771 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-term biological variation assessment (blood sampling once/week for five consecutive weeks)
Number of subjects: 43
Study 29303771 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term biological variation assessment (blood sampling once/day for five consecutive days)
Number of subjects: 43
Study 29303771 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference change values (RCV) for RBC and reticulocyte parameters
Number of subjects: 43
Study 26608702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 26608702 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 25397624 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine-montelukast (10mg/d montelukast and 5mg/d desloratadine for 6 weeks)
Number of subjects: 64
Study 25397624 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (no intervention)
Number of subjects: 64
Study 23531349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 2615
Study 23531349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 2615
Study 23531349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2615
Study 23531349 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 2615
Study 20373015 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Embryo Transfer (FET)
Number of subjects: 374
Study 20373015 — intervention group
Group type: COMPARATOR
Intervention: Fresh Embryo Transfer (ET)
Number of subjects: 374
Study 19040343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study 17217716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (10 microg kg‐1 min‐1, increasing to 40 microg kg‐1 min‐1 at 3 min intervals)
Number of subjects: 8
Study 17217716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 8
Study 14594938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF group), fraction size 1.2 Gy, mean total dose 73.4 Gy (range, 66-79.2 Gy)
Number of subjects: 42
Study 14594938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF group)
Number of subjects: 42
Study 14594938 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF group), fraction size 1.8-2.0 Gy, mean total dose 65.4 Gy (range, 60-70 Gy)
Number of subjects: 42
Study 14594938 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF group)
Number of subjects: 42
Study 10981168 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 10981168 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers
Number of subjects: 0
Study 10981168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9105649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 50
Study 9105649 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 50
Study 7901585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg daily) for 1 month (group A)
Number of subjects: 55
Study 7901585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg daily) for about 3 months (group B)
Number of subjects: 55
Study 7901585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no albendazole treatment)
Number of subjects: 55
Study 2939116 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 50‐600 mg/d
Number of subjects: 1382
Study 2939116 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 1382
Study 2939116 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1382
Study 31811742 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + Connective tissue graft (CTG)
Number of subjects: 30
Study 31811742 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) alone
Number of subjects: 30
Study 29738635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal packing
Number of subjects: 47
Study 29738635 — intervention group
Group type: COMPARATOR
Intervention: Hypopharyngeal packing
Number of subjects: 47
Study 28153824 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 27
Study 28153824 — intervention group
Group type: COMPARATOR
Intervention: Cidofovir
Number of subjects: 27
Study 25085036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (8% for induction, maintained at 2-4%)
Number of subjects: 24
Study 25085036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg bolus)
Number of subjects: 24
Study 23172975 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 50
Study 23172975 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (control)
Number of subjects: 50
Study 20965514 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 60
Study 20965514 — intervention group
Group type: COMPARATOR
Intervention: Nontreated (Control)
Number of subjects: 60
Study 18180681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 53
Study 18180681 — intervention group
Group type: COMPARATOR
Intervention: Balafilcon A lenses
Number of subjects: 53
Study 18180681 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-wear basis
Number of subjects: 53
Study 18180681 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-wear basis
Number of subjects: 53
Study 16385384 — intervention group
Group type: COMPARATOR
Intervention: s.c. infusion of saline (SAL)
Number of subjects: 7
Study 16385384 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1); LSC)
Number of subjects: 7
Study 16385384 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1)) in combination with a DPP‐4 inhibitor (IB)
Number of subjects: 7
Study 16385384 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of GLP‐1 (1.2 pmol kg(‐1) min(‐1); IV)
Number of subjects: 7
Study 16385384 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (9.6 pmol kg(‐1) min(‐1); HSC)
Number of subjects: 7
Study 12529091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1711
Study 12529091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711
Study 10678544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (3 pmol/kg per min)
Number of subjects: 7
Study 10678544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9118626 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05%
Number of subjects: 14
Study 9118626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:4 dilution of betamethasone dipropionate
Number of subjects: 14
Study 9118626 — intervention group
Group type: COMPARATOR
Intervention: Ointment base (control)
Number of subjects: 14
Study 1633753 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.32 mg/70 kg)
Number of subjects: 7
Study 1633753 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.75 mg/70 kg)
Number of subjects: 7
Study 1633753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6241386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal coronary angioplasty (group I)
Number of subjects: 107
Study 6241386 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group II)
Number of subjects: 107
Study 6241386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal coronary angioplasty
Number of subjects: 107
Study 6241386 — intervention group
Group type: EXPERIMENTAL
Intervention: Total coronary occlusion treatment
Number of subjects: 107
Study 30521147 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken breast consumption
Number of subjects: 0
Study 30202408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross myofascial release (MFR) of neck and upper limb in addition to conventional therapy (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Number of subjects: 40
Study 30202408 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Number of subjects: 40
Study 26446709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 69
Study 26446709 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy (ST)
Number of subjects: 69
Study 26446709 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 24489043 — intervention group
Group type: EXPERIMENTAL
Intervention: Well London community engagement programme
Number of subjects: 3986
Study 21320855 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume feeds at 300 ml/kg/day
Number of subjects: 64
Study 21320855 — intervention group
Group type: COMPARATOR
Intervention: Standard volume feeds at 200 ml/kg/day
Number of subjects: 64
Study 20561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume PEG + ascorbic acid
Number of subjects: 895
Study 20561621 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume PEG-electrolyte solution
Number of subjects: 895
Study 20561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dosage regimen
Number of subjects: 895
Study 20561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair/poor preparation
Number of subjects: 895
Study 20561621 — intervention group
Group type: COMPARATOR
Intervention: Non-split-dosage arm
Number of subjects: 895
Study 20561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 895
Study 20561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-split-dosage bowel preparation schedule
Number of subjects: 895
Study 17439381 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Number of subjects: 60
Study 17439381 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts
Number of subjects: 60
Study 17439381 — intervention group
Group type: COMPARATOR
Intervention: TLC diet alone
Number of subjects: 60
Study 15785257 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (thrust technique)
Number of subjects: 26
Study 15785257 — intervention group
Group type: EXPERIMENTAL
Intervention: Postisometric relaxation (mobilization)
Number of subjects: 26
Study 15785257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12409574 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensional technique
Number of subjects: 38
Study 12409574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidimensional technique
Number of subjects: 38
Study 12409574 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric technique
Number of subjects: 38
Study 11443509 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-adulthood BMI as a mortality predictor
Number of subjects: 14407
Study 11443509 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI as a covariate
Number of subjects: 14407
Study 11443509 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <20 kg/m2
Number of subjects: 14407
Study 9399714 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser guidewire (LW)
Number of subjects: 345
Study 7956713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=15)
Number of subjects: 21
Study 7956713 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=6)
Number of subjects: 21
Study 3628830 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.5 mg sc)
Number of subjects: 6
Study 3628830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30260273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) administered via intravenous infusion
Number of subjects: 84
Study 30260273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine responders
Number of subjects: 84
Study 27695423 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (200 mg/day)
Number of subjects: 19
Study 27695423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg/day)
Number of subjects: 19
Study 25624757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cycle ergometer exercise program
Number of subjects: 41
Study 25624757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 23619342 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐75‐homocholic acid taurine (Se‐75‐HCAT) administered orally
Number of subjects: 16
Study 20350153 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) as a full-mouth procedure after scaling and root planing (SRP)
Number of subjects: 24
Study 20350153 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with photosensitizer solution without laser irradiation
Number of subjects: 24
Study 20350153 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT group
Number of subjects: 24
Study 19052402 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 100 mg daily (group A)
Number of subjects: 55
Study 19052402 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 2 mg daily (group B)
Number of subjects: 55
Study 15876902 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/d
Number of subjects: 19
Study 15876902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12505565 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2044
Study 12505565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044
Study 10380021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 500 mg acetazolamide (Diamox) (Group 1)
Number of subjects: 63
Study 10380021 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 63
Study 8701509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water irrigation (HWI)
Number of subjects: 44
Study 8701509 — intervention group
Group type: COMPARATOR
Intervention: Tamponade
Number of subjects: 44
Study 1998656 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/colestipol therapy
Number of subjects: 0
Study 1998656 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel-determined consensus score
Number of subjects: 0
Study 31786871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 95
Study 31786871 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 95
Study 30089614 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest oxLDL quartile (≥28.81 μg/dL)
Number of subjects: 3019
Study 30089614 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 3019
Study 27329869 — intervention group
Group type: COMPARATOR
Intervention: Palacos bone cement
Number of subjects: 39
Study 27329869 — intervention group
Group type: EXPERIMENTAL
Intervention: Palamed bone cement
Number of subjects: 39
Study 24999157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day)
Number of subjects: 124
Study 24999157 — intervention group
Group type: COMPARATOR
Intervention: Standard albendazole (15 mg/kg per day)
Number of subjects: 124
Study 24999157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose albendazole (22.5 mg/kg per day)
Number of subjects: 124
Study 22553354 — intervention group
Group type: EXPERIMENTAL
Intervention: Betulinic acid (1 to 10 μmol/L)
Number of subjects: 2
Study 22553354 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA interference knockdown of Sp1, Sp3, Sp4
Number of subjects: 2
Study 22553354 — intervention group
Group type: EXPERIMENTAL
Intervention: Betulinic acid
Number of subjects: 2
Study 19756506 — intervention group
Group type: EXPERIMENTAL
Intervention: Original SAPS 3
Number of subjects: 1873
Study 19756506 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized SAPS 3 (SAPS 3-AUS)
Number of subjects: 1873
Study 17976264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose solution
Number of subjects: 0
Study 17976264 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef drink
Number of subjects: 0
Study 17976264 — intervention group
Group type: EXPERIMENTAL
Intervention: Shepherd's pie (solid meal)
Number of subjects: 0
Study 17976264 — intervention group
Group type: COMPARATOR
Intervention: Liquid foods (dextrose and beef drinks)
Number of subjects: 0